Table 4.
Univariate analysis of the clinical factors influencing the efficacy of eradication therapy n (%)
| Variable | Sequential therapy | P value | Hybrid therapy | P value |
| Resistance (n = 124) | n = 59 | n = 65 | ||
| Metronidazole | 0.22 | 0.74 | ||
| Susceptible | 32 (84.2) | 37 (94.9) | ||
| Resistant | 14 (66.7) | 25 (96.1) | ||
| Clarithromycin | 0.73 | 0.51 | ||
| Susceptible | 37 (77.1) | 54 (94.7) | ||
| Resistant | 9 (81.8) | 8 (100) | ||
| Tetracycline | 0.59 | NA | ||
| Susceptible | 45 (77.6) | 62 (95.4) | ||
| Resistant | 1 (100) | |||
| Levofloxacin | 0.46 | 0.45 | ||
| Susceptible | 36 (75.0) | 52 (94.5) | ||
| Resistant | 10 (90.9) | 10 (100) | ||
| Amoxicillin | NA | NA | ||
| Susceptible | 46 (78.0) | 62 (95.4) | ||
| Resistant | ||||
| Dual resistance | 0.66 | 0.65 | ||
| Present | 5 (71.4) | 4 (100) | ||
| Absent | 41 (78.8) | 58 (95.0) | ||
| Compliance | 0.47 | 0.66 | ||
| Good | 66 (79.5) | 78 (94.0) | ||
| Poor | 2 (100) | 3 (100) | ||
| Smoking | 0.2 | 0.31 | ||
| Present | 6 (100) | 14 (100) | ||
| Absent | 62 (78.5) | 67 (93.1) | ||
| Alcohol | 0.29 | 0.21 | ||
| Present | 16 (88.9) | 20 (100) | ||
| Absent | 52 (77.6) | 61 (92.4) | ||
| Gastroduodenal disease | 0.91 | 0.57 | ||
| Non-ulcer dyspepsia | 43 (79.6) | 38 (92.7) | ||
| Peptic ulcer | 25 (80.6) | 43 (95.6) | ||
| Bacterial density | 0.31 | 0.4 | ||
| Mild | 4 (100) | 7 (87.5) | ||
| Moderate/marked | 64 (79.0) | 74 (94.9) |